So, not COVID related, however, this is REALLY exciting news I wanted to share. Only a Phase I study, BUT clinical trial results for HIV vaccine candidate eOD-GT8 60mer have shown 97% of participants (ALL but one) generated an antibody response against HIV! That is ASTOUNDING.
Vaccine candidate, eOD-GT8 60mer, had a favorable safety profile and induced broadly neutralizing antibody precursors in 97%, or all but one, of the 36 recipients. This study is a joint efforts between researchers from Scripps Research, the Fred Hutchinson Cancer Center,
the National Institutes of Health (NIH) and other institutions in the United States and Sweden.

The clinical trial results were published Thursday on World AIDS Day in the journal Science, and establish "clinical proof of concept" in support of developing boosting regimens to
induce immune responses against HIV infection, for which there is no cure and which can cause acquired immunodeficiency syndrome (AIDS).

The eOD-GT8 60mer vaccine candidate is germline-targeting, meaning it is designed to induce the production of broadly neutralizing antibodies
by targeting and stimulating the right antibody-producing cells. Broadly neutralizing antibodies are known to neutralize many genetic variants of HIV, but in the past, they have been difficult to elicit by vaccination. That is why this clinical trial data is SO ENCOURAGING.
The study findings suggest that a two-dose regimen of the vaccine, given eight weeks apart, can elicit immune responses against HIV. The International AIDS Vaccine Initiative announced the start of this Phase 1 clinical trial in 2018, to evaluate the safety of eOD-GT8 60mer
and the immune responses it is able to induce. The trial included a total of 48 healthy adults, ages 18 to 50, who were enrolled at two sites: George Washington University in Washington and Fred Hutchinson Cancer Center in Seattle. Among the participants, 18 received a
20-microgram dose of the vaccine and, eight weeks later, a same-size dose of the vaccine with an adjuvant; 18 received a 100-microgram dose of the vaccine and, eight weeks later, a same-size dose of the vaccine with an adjuvant; and 12 received two doses of a saline placebo,
eight weeks apart. The adjuvant is called AS01B, developed by the pharmaceutical company GSK. The vaccines and placebo were given into the arm muscle.
Researchers collected and analyzed immune cells from the blood and lymph nodes of participants during the study. They specifically examined how B cells, a type of white blood cell that makes antibodies in the immune system, responded to the vaccine. Researchers found no serious
adverse events reported among the study participants, and no participants acquired HIV infection during the study. About 97% -or all but one - of the 48 study participants reported local or systemic adverse events that were generally mild or moderate, such as pain at the
injection site, malaise and headache. In most cases, these events were resolved within a day or two. After the first immunization, all vaccine recipients but no placebo recipients were found to produce antibodies elicited by the eOD-GT8 60mer vaccine. Those vaccine-induced
responses INCREASED after the second vaccination. By showing that broadly neutralizing antibodies CAN be induced by a vaccine, this new study could help inform the development of other types of immunizations, not just HIV vaccines! This is an EXTREMELY important step forward.
I’ll be sure to post more updates on these studies. In the meantime, you can read all of this and more here:…………

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Chise 🧬🧫🦠🔬💉🥼🥽

Chise 🧬🧫🦠🔬💉🥼🥽 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

Nov 29
“I trust my immune system. I don’t need a vaccine.”

Ok, I trust mine to protect me too. Which is why I trained it extensively on what the virus looks like so it can handle it.

Boxers don’t enter the ring without a plan. It’s the punch you don’t see coming that knocks you out.
While we are here, I recommend reading my latest master thread with current studies ALL about the updated bivalent boosters:

The Body’s Natural Response (WITH a Caveat)
So how do vaccines help? Vaccines can contain weakened or inactive parts of a particular organism (antigen) that triggers an immune response within the body. Newer vaccines contain the blueprint for producing antigens rather than the antigen itself.
Read 14 tweets
Nov 25
Them: The COVID-19 vaccines don’t work. The majority of hospitalizations/deaths/infections are fully vaccinated.

Me: Base Rate Fallacy would like a word with you. Image
Let’s try something. Most people get this question wrong. Can you solve it? A town has only two colours of car: 85% are blue and 15% are green. A person witnesses a hit-and-run and says they saw a green car. If witnesses identify the colour of cars correctly 80% of the time, what
are the chances the car is actually green? You might have said 80%. A lot of people do. The correct answer is 41%. The reason so many struggle with this question is due to the Base Rate Fallacy. Our brains tend to ignore statistical information (aka base rates) and focus on
Read 14 tweets
Nov 14
Encouraging news for your day! BOTH of Moderna's Omicron bivalent booster vaccines mRNA-1273.214 AND mRNA-1273.222 demonstrated SUPERIOR neutralizing antibody responses against ALL variants of concern INCLUDING Omicron subvariants BA.4, BA.5, AND BQ.1.1! Let’s talk about that!🧵
PLEASE NOTE. SUPERIORITY CONTINUED 3 MONTHS AFTER ADMINISTRATION, NOT ONLY FOR 3 MONTHS. Just wanted to clarify that statement before comments started popping up. In addition, this study is in regards to NEUTRALIZING ANTIBODY RESPONSES ONLY. Let’s continue.
If you guys remember, I wrote on Moderna's bivalent booster vaccine mRNA-1273.214, which has equal mRNA amounts of ancestral SARS-CoV-2 and Omicron (BA.1) variant spike proteins. This data has since been PEER-REVIEWED in NEJM as of September.
Read 14 tweets
Nov 11
Good Morning. ☀️
I’ll actually use this to make a little bit of a master thread by compiling them here for you along with some other resources on bivalent boosters!
Read 13 tweets
Nov 7
Encouraging news for your day! A recent study out of Emory University, Stanford University, and NIAID shows mRNA bivalent boosters ENHANCES neutralization against Omicron subvariants BA.2.75.2 and BQ.1.1! This study used a LIVE virus neutralization assay. Let’s talk about that!🧵
NOTE: This study is in regards to NEUTRALIZING ANTIBODY RESPONSES ONLY. YES, there is much more to our immune response than just nAbs. Live neutralization assays as opposed to Pseudovirus neutralization assays tend to be more accurate. Image
Using a live virus neutralization assay, researchers evaluated serum samples from individuals who had received either one or two monovalent boosters or the bivalent booster to determine neutralizing activity against wild-type (WA1/2020) virus and Omicron subvariants BA.1, BA.5,
Read 15 tweets
Nov 1
This is HUGE news! Pfizer’s bivalent Respiratory Syncytial Virus (RSV) vaccine candidate (RSVpreF) demonstrated stellar efficacy (81.8% against SEVERE lower respiratory illness). Pfizer plans to submit by end of this year! If approved, this will be THE FIRST RSV vaccine!
Vaccine efficacy of 81.8% was observed against severe medically attended lower respiratory tract illness due to RSV in infants from birth through the first 90 days of life with high efficacy of 69.4% demonstrated through the first six months of life.
The RSVpreF investigational vaccine was well-tolerated with no safety concerns for both vaccinated individuals and their newborns. Results met one of the study protocol’s pre-specified regulatory success criteria, and Pfizer plans to submitits first regulatory application by end
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!


0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy


3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!